Trial design for evaluating novel treatments during an outbreak of an infectious disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Trials

• Publication date

  2016-01-14

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1177/1740774515617740PMID 26768556PMCID PMC5856305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates

  2015cited by this paper
• Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease

  2015cited by this paper
• Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

  2015cited by this paper
• Bayesian methods for the design and interpretation of clinical trials in very rare diseases

  2014cited by this paper
• Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.

  2014cited by this paper
• An exact method for analysis following a two‐stage phase II cancer clinical trial

  2010cited by this paper
• Bayesian sample size for exploratory clinical trials incorporating historical data

  2008cited by this paper
• Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment

  2003cited by this paper
• Overrunning and underrunning in sequential clinical trials.

  1992cited by this paper
• Designing phase II studies in the context of a programme of clinical research.

  1985cited by this paper
• Phase II clinical trials.

  1977cited by this paper

• A multi-arm multi-stage design for trials with all pairwise testing

  2025cites this paper
• Characteristics analysis for clinical study design relating to COVID-19 based on the database of ClinicalTrials.gov

  2022cites this paper
• Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients

  2020cites this paper
• Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak

  2020cites this paper
• Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil

  2020cites this paper
• A careful biomedicine? Generalization and abstraction in RCTs

  2019cites this paper
• The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research

  2019cites this paper
• Rigorous Clinical Trial Design in Public Health Emergencies Is Essential

  2018cites this paper
• The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

  2018cites this paper
• Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives

  2017cites this paper
• From Standardization to Adaptation: Clinical Trials and the Moral Economy of Anticipation

  2017cites this paper
• Improving readiness for recruitment through simulated trial activation: the Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial

  2017cites this paper
• Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa

  2017cites this paper
• A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

  2016cites this paper
• A comparison of the barely Bayesian design with the triangular test for clinical trials in infectious diseases

  2016cites this paper
• The Ebola clinical trials: a precedent for research ethics in disasters

  2016cites this paper